Skip to content
ATLAS PREP HQ
Sleep

DSIP

Delta sleep-inducing peptide, a naturally occurring nonapeptide

Delta sleep-inducing peptide research examining sleep architecture, slow-wave sleep, and stress regulation.

Limited Human Evidence

Route

Subcutaneous in the community page

Common format

5 mg vial

Research focus

sleep architecture

Evidence level

Limited Human Evidence

Typical cycle

4–8 weeks

Sleep research motifSleep

DSIP in 30 seconds

Atlas Fast Read

What it is

Delta sleep-inducing peptide, a naturally occurring nonapeptide

Why people care

Delta sleep-inducing peptide research examining sleep architecture, slow-wave sleep, and stress regulation.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

DSIP has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is DSIP?

DSIP is delta sleep-inducing peptide, a naturally occurring nonapeptide. Delta sleep-inducing peptide research examining sleep architecture, slow-wave sleep, and stress regulation.

Delta sleep-inducing peptide was first isolated in the 1970s after experiments involving sleep-related brain signals. Human sleep studies followed, but results were inconsistent and the peptide never became an established sleep medicine.

Mechanism

How it works

Its exact receptor and physiologic role remain uncertain. Proposed effects include modulation of sleep-stage regulation, GABAergic/opioid systems, and hypothalamic-pituitary-adrenal signaling, but the mechanism has never been firmly established in humans.

Research areas

sleep architectureslow-wave sleepstress/HPA axispain/addiction research

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Small human studies dating back decades investigated DSIP for sleep and related conditions, but results were inconsistent and the biology remains uncertain. It never developed into an established evidence-based sleep treatment.

Preclinical evidence

Animal work suggests effects on sleep, stress, pain, and neuroendocrine signaling, but the peptide's receptor and physiologic role remain uncertain. Preclinical findings have not translated cleanly into consistent human sleep outcomes.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community research reference: 100–300 mcg/day, with some experimental protocols titrating to 500 mcg. There is no established clinical dose.

Frequency

Once daily.

Timing

Typically evening before bedtime in research/community use.

Route

Subcutaneous in the community page; historic human studies used varying routes.

Cycle length

4–8 weeks

Reconstitution

Community reference: 0.5 mL bacteriostatic water per 5 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

Sleep diary or wearable metrics, daytime sleepiness, mood and BP; cortisol testing is optional/research-oriented rather than a validated requirement.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Systematic human safety data are limited. Reported or plausible effects include headache, dizziness, fatigue, irritability, sleep changes, nausea and injection/nasal-site irritation depending on route.

Contraindications

No validated broad contraindication profile exists. Avoid unsupervised use in pregnancy/breastfeeding, severe psychiatric instability, seizure disorders or major neurologic disease unless the research/clinical protocol specifically addresses it.

Interactions

Formal interaction studies are limited. CNS-active medicines, sedatives, stimulants, antidepressants, anxiolytics and anticonvulsants may alter or obscure effects and should be reviewed clinically.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

DSIP has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.